Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study

Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G Schulz, Wilhelm Kuker, Ziyah Mehta, Peter M Rothwell, Oxford Vascular Study, Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G Schulz, Wilhelm Kuker, Ziyah Mehta, Peter M Rothwell, Oxford Vascular Study

Abstract

Background: A third of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary prevention. If these events are due to occult atheroma, the risk-factor profile and coronary prognosis should resemble that of overt large artery events. If they have a cardioembolic cause, the risk of future cardioembolic events should be increased. We aimed to assess the burden, outcome, risk factors, and long-term prognosis of cryptogenic TIA and stroke.

Methods: In a population-based study in Oxfordshire, UK, among patients with a first TIA or ischaemic stroke from April 1, 2002, to March 31, 2014, we compared cryptogenic events versus other causative subtypes according to the TOAST classification. We compared markers of atherosclerosis (ie, risk factors, coronary and peripheral arterial disease, asymptomatic carotid stenosis, and 10-year risk of acute coronary events) and of cardioembolism (ie, risk of cardioembolic stroke, systemic emboli, and new atrial fibrillation [AF] during follow-up, and minor-risk echocardiographic abnormalities and subclinical paroxysmal AF at baseline in patients with index events between 2010 and 2014).

Findings: Among 2555 patients, 812 (32%) had cryptogenic events (incidence of cryptogenic stroke 0·36 per 1000 population per year, 95% CI 0·23-0·49). Death or dependency at 6 months was similar after cryptogenic stroke compared with non-cardioembolic stroke (23% vs 27% for large artery and small vessel subtypes combined; p=0·26) as was the 10-year risk of recurrence (32% vs 27%; p=0·91). However, the cryptogenic group had fewer atherosclerotic risk factors than the large artery disease (p<0·0001), small vessel disease (p=0·001), and cardioembolic (p=0·008) groups. Compared with patients with large artery events, those with cryptogenic events had less hypertension (adjusted odds ratio [OR] 0·41, 95% CI 0·30-0·56; p<0·0001), diabetes (0·62, 0·43-0·90; p=0·01), peripheral vascular disease (0·27, 0·17-0·45; p<0·0001), hypercholesterolaemia (0·53, 0·40-0·70; p<0·0001), and history of smoking (0·68, 0·51-0·92; p=0·01), and compared with small vessel and cardioembolic subtypes, they had no excess risk of asymptomatic carotid disease (adjusted OR 0·64, 95% CI 0·37-1·11; p=0·11) or acute coronary events (adjusted hazard ratio [HR] 0·76, 95% CI 0·49-1·18; p=0·22) during follow-up. Compared with large artery and small vessel subtypes combined, patients with cryptogenic events also had no excess of minor-risk echocardiographic abnormalities (cryptogenic 37% vs 45%; p=0·18) or paroxysmal AF (6% vs 10%; p=0·17) at baseline or of new AF (adjusted HR 1·23, 0·78-1·95; p=0·37) or presumed cardioembolic events (1·16, 0·62-2·17; p=0·64) during follow-up.

Interpretation: The clinical burden of cryptogenic TIA and stroke is substantial. Although stroke recurrence rates are comparable with other subtypes, cryptogenic events have the fewest atherosclerotic markers and no excess of cardioembolic markers.

Funding: Wellcome Trust, Wolfson Foundation, UK Stroke Association, British Heart Foundation, Dunhill Medical Trust, National Institute for Health Research, Medical Research Council, and the NIHR Oxford Biomedical Research Centre.

Copyright © 2015 Li et al. Open Access article distributed under the terms of CC BY-NC-ND. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Number of atherosclerotic risk factors and frequency of comorbid atherosclerotic disease in different transient ischaemic attack and ischaemic stroke subtypes Frequencies of risk factors and comorbid disease are shown (A) overall and for (B) females and (C) males. Data on smoking status were missing in four patients with cardioembolic events and two patients with cryptogenic events. Risk factors were male sex, hypertension, diabetes, hypercholesterolaemia, and history of smoking. Male sex was not taken into account in the stratification analysis by sex (ie, B and C). p values are for heterogeneity among all subtypes using the χ2 test. ESUS=embolic strokes of undetermined source. LAD=large artery disease. PVD=peripheral vascular disease. SVD=small vessel disease. *Asymptomatic carotid stenosis ≥50% at bifurcation.
Figure 2
Figure 2
Severity of stenosis at the asymptomatic carotid bifurcation in different transient ischaemic attack and ischaemic stroke subtypes Carotid events were calculated as carotid stenosis (%) at the asymptomatic side; posterior circulation events were calculated as mean carotid stenosis (%) of both carotid arteries at the bifurcation. p values are for the difference of stenosis distribution between cryptogenic and other subtypes.
Figure 3
Figure 3
10-year absolute risks of acute coronary events, cardioembolic events, and recurrent ischaemic stroke TIA=transient ischaemic attack. *Consisted of recurrent cardioembolic stroke, acute embolic limb ischaemia, and acute embolic visceral embolisation caused by presumed cardioembolism.

References

    1. Amarenco P. Cryptogenic stroke, aortic arch atheroma, patent foramen ovale, and the risk of stroke. Cerebrovasc Dis. 2005;20(suppl 2):68–74.
    1. Bang OY, Lee PH, Joo SY, Lee JS, Joo IS, Huh K. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol. 2003;54:227–234.
    1. Hart RG, Diener HC, Coutts SB. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–438.
    1. Ntaios G, Papavasileiou V, Milionis H. Embolic strokes of undetermined source in the athens stroke registry: a descriptive analysis. Stroke. 2015;46:176–181.
    1. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis. 2009;27:502–508.
    1. Gu X, He Y, Li Z. Comparison of frequencies of patent foramen ovale and thoracic aortic atherosclerosis in patients with cryptogenic ischemic stroke undergoing transesophageal echocardiography. Am J Cardiol. 2011;108:1815–1819.
    1. Sanna T, Diener HC, Passman RS. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–2486.
    1. Gladstone DJ, Spring M, Dorian P. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–2477.
    1. O'Donnell MJ, Xavier D, Liu L. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–123.
    1. Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke. 2003;34:2050–2059.
    1. Song YM, Kwon SU, Sung J. Different risk factor profiles between subtypes of ischemic stroke. A case-control study in Korean men. Eur J Epidemiol. 2005;20:605–612.
    1. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet. 2000;355:19–24.
    1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.
    1. Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
    1. Bang OY, Lee PH, Yeo SH, Kim JW, Joo IS, Huh K. Non-cardioembolic mechanisms in cryptogenic stroke: clinical and diffusion-weighted imaging features. J Clin Neurol. 2005;1:50–58.
    1. Karttunen V, Alfthan G, Hiltunen L. Risk factors for cryptogenic ischaemic stroke. Eur J Neurol. 2002;9:625–632.
    1. Rothwell PM, Coull AJ, Giles MF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study) Lancet. 2004;363:1925–1933.
    1. Feigin V, Hoorn SV. How to study stroke incidence. Lancet. 2004;363:1920.
    1. Adams HP, Jr, Bendixen BH, Kappelle LJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
    1. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005;36:891–901.
    1. Ay H, Benner T, Arsava EM. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38:2979–2984.
    1. Amarenco P, Cohen A, Tzourio C. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331:1474–1479.
    1. The French Study of Aortic Plaques in Stroke Group Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. 1996;334:1216–1221.
    1. Meissner I, Khandheria BK, Sheps SG. Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol. 2004;44:1018–1024.
    1. Russo C, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: the Aortic Plaques and Risk of Ischemic Stroke (APRIS) study. Stroke. 2009;40:2313–2318.
    1. Agmon Y, Khandheria BK, Meissner I. Relation of coronary artery disease and cerebrovascular disease with atherosclerosis of the thoracic aorta in the general population. Am J Cardiol. 2002;89:262–267.
    1. Katsanos AH, Giannopoulos S, Kosmidou M. Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis. Stroke. 2014;45:1764–1770.
    1. Jickling GC, Stamova B, Ander BP. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke. 2012;43:2036–2041.
    1. Brambatti M, Connolly SJ, Gold MR. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129:2094–2099.
    1. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke. A meta-analysis of case-control studies. Neurology. 2000;55:1172–1179.
    1. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–2268.
    1. Diener HC, Connolly S, Easton J, Smith J, Duffy C, Bruckmann M. Rationale, objectives and design of a secondary stroke prevention study of dabigatran etexilate versus acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT-ESUS) Cerebrovasc Dis. 2014;37:261.
    1. The NAVIGATE ESUS trial Population Health Research Institute. (accessed Feb 8, 2015).

Source: PubMed

3
Subscribe